Bradley & Co Private Wealth Management’s ALX Oncology ALXO Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2K	Hold	1,000	–	–	﹤0.01%	185
2025 Q4	$1.13K	Hold	1,000	–	–	﹤0.01%	196
2025 Q3	$1.83K	Hold	1,000	–	–	﹤0.01%	183
2025 Q2	$415	Hold	1,000	–	–	﹤0.01%	185
2025 Q1	$623	Hold	1,000	–	–	﹤0.01%	179
2024 Q4	$1.67K	Buy	+1,000	New	+$1.54K	﹤0.01%	165
2024 Q2	$6.03K	Hold	1,000	–	–	﹤0.01%	128
2024 Q1	$11.2K	Hold	1,000	–	–	0.01%	119
2023 Q4	$14.9K	Hold	1,000	–	–	0.01%	110
2023 Q3	$4.8K	Hold	1,000	–	–	0.01%	133
2023 Q2	$7.51K	Hold	1,000	–	–	0.01%	120
2023 Q1	$4.52K	Hold	1,000	–	–	0.01%	135
2022 Q4	$11.3K	Hold	1,000	–	–	0.01%	113
2022 Q3	$10K	Hold	1,000	–	–	0.01%	123
2022 Q2	$8K	Buy	+1,000	New	+$10.9K	0.01%	138

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Bradley & Co Private Wealth Management's ALXO Position: Q1 2026 in Review

Bradley & Co Private Wealth Management held its ALX Oncology (ALXO) position steady in Q1 2026 at 1,000 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #185.

Bradley & Co Private Wealth Management first reported a position in ALXO in Q2 2022 and has held it in 15 quarters since. The position peaked at $14.9K in Q4 2023. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Bradley & Co Private Wealth Management held 1,000 shares of ALX Oncology worth $2K as of Q1 2026.
Bradley & Co Private Wealth Management left its ALX Oncology share count unchanged in Q1 2026.
ALX Oncology made up ﹤0.01% of Bradley & Co Private Wealth Management's portfolio in Q1 2026, its #185 holding.
Bradley & Co Private Wealth Management first reported a position in ALX Oncology in Q2 2022 and has held it in 15 quarters since.
Bradley & Co Private Wealth Management's ALX Oncology position peaked at $14.9K in Q4 2023.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Bradley & Co Private Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.